Navigation Links
Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)

LONDON, November 18 /PRNewswire/ --

- New Report Highlights Global Economic Burden of the Disease

- An Estimated Two Billion Work Hours Lost Each Week

COPD Uncovered, a new report issued today reveals for the first time that people between the ages of 40 to 65 are emerging as the new face of this disease. Authored by Education for Health and other leading experts, the report uncovers a new, younger majority of COPD patients(1) who are in the prime of their career, and financially responsible for the care of their children and aging parents. The authors call for policymakers to read the report and challenge their thinking on how COPD should be addressed in this critical age group who are highly depended upon by society as leading wage earners(2,3).

COPD affects 210 million people and is predicted to be the third leading cause of death globally in ten years time(4). A severely debilitating disease, COPD dramatically impairs the productivity of this population. In fact, the report found that people between 40 and 65 with COPD miss as many as ten hours of work per week because of their condition(5). On a global scale, that represents more than two billion working hours lost each week worldwide. Additionally, COPD causes nearly 28,000 years of lost productivity annually(6). The report deduces that if left unchecked, COPD could have significant global workforce and economic implications on patients, families, employers and society as the disease escalates.

"Given the potential economic impact, it is critical that 40 to 65 year olds with COPD are able to lead an active and productive life," said Monica Fletcher, Chief Executive of Education for Health. "In releasing this report we want to spark an important global dialogue with key global stakeholders on how best to invest in earlier diagnosis and the management of these younger patients."

    Other key insights from the report include:

    - COPD costs more than asthma and diabetes - The cost of COPD
      exceeds that of many other serious, long-term conditions including
      asthma and diabetes(7). The worldwide burden of COPD is nearly double
      that of diabetes and it causes more deaths(6).

    - Effective COPD treatment must look beyond smoking cessation - It is
      true that the primary cause of COPD is cigarette smoke(8) and smoking
      cessation is an important part of COPD management. Yet many former
      smokers develop symptoms and are diagnosed a decade or two after they
      stopped. In fact, even if all smoking stopped today, the effect on COPD
      statistics would not be seen for up to 20 years(9).

    - COPD puts pressure on healthcare systems - One in six
      European and U.S. patients had visited the ER or hospital in a six
      month period 2006-20075. Extrapolating these figures indicates that up
      to 64 million COPD patients globally may be admitted to hospital due to
      their condition each year. Additionally, a large majority of COPD
      patients suffer from co-morbidities, such as heart disease, high blood
      pressure and diabetes(10-13). In fact, 40 percent suffer from heart
      disease10 and as many as 42 percent from high blood pressure(12,13).
    - Families may also face burden - More women than men are now being
      be diagnosed with COPD(14) - a patient segment central to family care.

About COPD

Chronic obstructive pulmonary disease (COPD) is a debilitating, life-threatening and progressive lung disease that interferes with normal breathing(8). It is thought to cause around three million deaths per year - on average one person every 10 seconds(4). COPD refers to emphysema and chronic bronchitis - two commonly co-existing diseases of the lung. Due to lung deterioration, people with COPD experience symptoms like chronic shortness of breath and cough that impact the ability to lead an active and productive life(8). There is no cure for COPD but it can be treated.

About COPD Uncovered

COPD Uncovered represents the combined efforts of a multi-disciplinary committee of international experts, coming together to bring forward some of the most burning issues in COPD today. Their aim is to highlight the impact of COPD in an understudied and ignored patient segment between the ages of 40 and 65.

The COPD Uncovered initiative is a compendium of research and analysis undertaken by experts in respiratory health. This initiative is sponsored by Novartis Pharma AG and is administered by a Secretariat from Chandler Chicco Companies (CCC). The studies underlying the COPD Uncovered Report were commissioned by Novartis Pharma AG.

Following the release of this report, the COPD Uncovered experts are conducting further quantitative research into the direct and indirect costs of the disease among this age group. In 2010, they expect to release the results of the study that will look at the specific impact of COPD on the daily lives of more than 2,000 COPD patients aged 45-67 from the U.S., the UK, Germany, Brazil, China and Turkey.

About the Authors

The COPD Uncovered Report, issued on World COPD Day 2009, is authored by the following individuals, supported by Novartis with editorial assistance from medical education specialists from CCC:

    - Monica Fletcher, Chief Executive, Education for Health and National
      Respiratory Training Center, principle lead for COPD Uncovered

    - Dr Marianella Salapatas, President, European Federation of Allergy and
      Airways Diseases Patients' Associations

    - Professor Thys van der Molen, Department of General Practice,
       University of Groningen

    - John Walsh, President and CEO, COPD Foundation

    To download a copy of the COPD Uncovered report, visit:


    For press enquiries, please contact:

    Sue Davis Russell - PA to Chief Executive
    Education for Health
    Tel: +44-(0)1926-836841, Email:

    Candy Perry - Head of Corporate Communications and External Affairs
    Education for Health
    Tel: +44-(0)1926-836995, Email:

    Visit our website at:

SOURCE Education for Health

SOURCE Education for Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
Breaking Biology News(10 mins):